FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bert La Du

Research Profile

Chemicals & Drugs

Concepts & Ideas

Genes & Molecular Sequences

Amino Acid Sequences

Physiology

Phenotype

Phenomena

Living Beings

Rabbits

Procedures

Polymerase Chain Reaction

Co-author Network

Publications

TOP 3
John F Teiber; Scott S Billecke; Bert N La Du; Dragomir I Draganov
Estrogen esters as substrates for human paraoxonases.
Dragomir I Draganov; John F Teiber; Audrey Speelman; Yoichi Osawa; Roger K Sunahara; Bert N La Du
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.
John F Teiber; Dragomir I Draganov; Bert N La Du
Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bert La Du (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: John F Teiber; Scott S Billecke; Bert N La Du; Dragomir I Draganov
Estrogen esters as substrates for human paraoxonases.
Archives of biochemistry and biophysics 2007;461(1):24-9.
2005: Dragomir I Draganov; John F Teiber; Audrey Speelman; Yoichi Osawa; Roger K Sunahara; Bert N La Du
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.
Journal of lipid research 2005;46(6):1239-47.
2004: John F Teiber; Dragomir I Draganov; Bert N La Du
Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH.
Journal of lipid research 2004;45(12):2260-8.
2004: Dragomir I Draganov; Bert N La Du
Pharmacogenetics of paraoxonases: a brief review.
Naunyn-Schmiedeberg's archives of pharmacology 2004;369(1):78-88.
2003: John F Teiber; Dragomir I Draganov; Bert N La Du
Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3.
Biochemical pharmacology 2003;66(6):887-96.
2003: Bert N La Du
Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(8):1317-8.
2003: Mira Rosenblat; Dragomir I Draganov; Catherine E Watson; Charles L Bisgaier; Bert N La Du; Michael Aviram
Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(3):468-74.
2003: Zakaria Ahmed; Saeid Babaei; Graham F Maguire; Dragomir I Draganov; Arnis Kuksis; Bert N La Du; Philip W Connelly
Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine.
Cardiovascular research 2003;57(1):225-31.
2002: Tetsuo Satoh; Palmer Taylor; William F Bosron; Sonal P Sanghani; Masakiyo Hosokawa; Bert N La Du
Current progress on esterases: from molecular structure to function.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(5):488-93.
2002: Zakaria Ahmed; Amir Ravandi; Graham F Maguire; Andrew Emili; Dragomir I Draganov; Bert N La Du; Arnis Kuksis; Philip W Connelly
Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite.
Biochemical and biophysical research communications 2002;290(1):391-6.
2001: Zakaria Ahmed; Amir Ravandi; Graham F Maguire; Andrew Emili; Dragomir I Draganov; Bert N La Du; Arnis Kuksis; Philip W Connelly
Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor.
The Journal of biological chemistry 2001;276(27):24473-81.
2001: Bert N La Du; Scott S Billecke; C Hsu; Robert W Haley; C A Broomfield
Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 2):566-9.
2001: Catherine E Watson; Dragomir I Draganov; Scott S Billecke; Charles L Bisgaier; Bert N La Du
Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R.
Pharmacogenetics 2001;11(2):123-34.
2000: Scott S Billecke; Dragomir I Draganov; Raymond E Counsell; PL Stetson; C Watson; C Hsu; Bert N La Du
Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(11):1335-42.
2000: Dragomir I Draganov; PL Stetson; Catherine E Watson; Scott S Billecke; Bert N La Du
Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation.
The Journal of biological chemistry 2000;275(43):33435-42.
1999: Mohamed Naguib; M Gomaa; Abdulhamid H Samarkandi; D R Bevan; A K Akkielah; C Watson; Scott S Billecke; Bert N La Du
Increased plasma cholinesterase activity and mivacurium resistance: report of a family.
Anesthesia and analgesia 1999;89(6):1579-82.
1999: RC Sorenson; Charles L Bisgaier; Michael Aviram; C Hsu; Scott S Billecke; Bert N La Du
Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(9):2214-25.
1999: Robert W Haley; Scott S Billecke; Bert N La Du
Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans.
Toxicology and applied pharmacology 1999;157(3):227-33.
1999: Bert N La Du; Clement E Furlong; E Reiner
Recommended nomenclature system for the paraoxonases.
Chemico-biological interactions 1999;119-120():599-601.
1999: Bert N La Du; Michael Aviram; Scott S Billecke; Mohamad Navab; SL Primo-Parmo; RC Sorenson; Theodore J Standiford
On the physiological role(s) of the paraoxonases.
Chemico-biological interactions 1999;119-120():379-88.
1999: Scott S Billecke; SL Primo-Parmo; C S Dunlop; Jonathan A Doorn; Bert N La Du; C A Broomfield
Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate.
Chemico-biological interactions 1999;119-120():251-6.
1999: RC Sorenson; Michael Aviram; Charles L Bisgaier; Scott S Billecke; C Hsu; Bert N La Du
Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase.
Chemico-biological interactions 1999;119-120():243-9.
1999: Jonathan A Doorn; RC Sorenson; Scott S Billecke; C Hsu; Bert N La Du
Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase.
Chemico-biological interactions 1999;119-120():235-41.
1999: Michael Aviram; Mira Rosenblat; Scott S Billecke; J Erogul; RC Sorenson; Charles L Bisgaier; Roger S Newton; Bert N La Du
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
Free radical biology & medicine 1999;26(7-8):892-904.
1998: Mohamad Navab; Susan Hama; Greg Hough; Catherine C Hedrick; RC Sorenson; Bert N La Du; J A Kobashigawa; Gregg C Fonarow; Judith A Berliner; Hillel Laks; Alan M Fogelman
High density associated enzymes: their role in vascular biology.
Current opinion in lipidology 1998;9(5):449-56.
1998: Michael Aviram; Scott S Billecke; RC Sorenson; Charles L Bisgaier; R Newton; Mira Rosenblat; J Erogul; C Hsu; C Dunlop; Bert N La Du
Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(10):1617-24.
1998: C L Kuo; Bert N La Du
Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(7):653-60.
1998: Michael Aviram; Mira Rosenblat; Charles L Bisgaier; Roger S Newton; SL Primo-Parmo; Bert N La Du
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
The Journal of clinical investigation 1998;101(8):1581-90.
1998: Bert N La Du
Are we ready to try to cure alkaptonuria?
American journal of human genetics 1998;62(4):765-7.
1997: J B Hallagan; Bert N La Du; M W Pariza; J M Putnam; J F Borzelleca
Assessment of cassia gum.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 1997;35(6):625-32.
1997: Mohamad Navab; S Hama-Levy; Brian J Van Lenten; Gregg C Fonarow; C J Cardinez; Lawrence W Castellani; Marie-Luise Brennan; Aldons J Lusis; Alan M Fogelman; Bert N La Du
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.
The Journal of clinical investigation 1997;99(8):2005-19.
1997: SL Primo-Parmo; H Lightstone; Bert N La Du
Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase.
Pharmacogenetics 1997;7(1):27-34.
1996: SL Primo-Parmo; RC Sorenson; J Teiber; Bert N La Du
The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.
Genomics 1996;33(3):498-507.
1996: SL Primo-Parmo; Cynthia F Bartels; B Wiersema; Abraham F L Van Der Spek; Jeffrey W Innis; Bert N La Du
Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene.
American journal of human genetics 1996;58(1):52-64.
1995: RC Sorenson; SL Primo-Parmo; Sally A Camper; Bert N La Du
The genetic mapping and gene structure of mouse paraoxonase/arylesterase.
Genomics 1995;30(3):431-8.
1995: Andrew D Watson; Judith A Berliner; Susan Hama; Bert N La Du; Kym F Faull; Alan M Fogelman; Mohamad Navab
Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.
The Journal of clinical investigation 1995;96(6):2882-91.
1995: Brian J Van Lenten; Susan Hama; Frederick C de Beer; D M Stafforini; T M McIntyre; S M Prescott; Bert N La Du; Alan M Fogelman; Mohamad Navab
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.
The Journal of clinical investigation 1995;96(6):2758-67.
1995: CL Kuo; Bert N La Du
Comparison of purified human and rabbit serum paraoxonases.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(9):935-44.
1995: RC Sorenson; SL Primo-Parmo; CL Kuo; S Adkins; Oksana Lockridge; Bert N La Du
Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(16):7187-91.
1995: C P Greenberg; SL Primo-Parmo; E J Pantuck; Bert N La Du
Prolonged response to succinylcholine: a new variant of plasma cholinesterase that is identified as normal by traditional phenotyping methods.
Anesthesia and analgesia 1995;81(2):419-21.
1993: Bert N La Du; S Adkins; CL Kuo; D Lipsig
Studies on human serum paraoxonase/arylesterase.
Chemico-biological interactions 1993;87(1-3):25-34.
1993: C P Nogueira; D A Evans; Bert N La Du
The paraoxonase polymorphism in a Saudi Arabian population.
Pharmacogenetics 1993;3(3):144-9.
1993: S Adkins; K N Gan; M Mody; Bert N La Du
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.
American journal of human genetics 1993;52(3):598-608.
1992: C P Nogueira; Cynthia F Bartels; M C McGuire; S Adkins; T Lubrano; H M Rubinstein; H Lightstone; Abraham F L Van Der Spek; Oksana Lockridge; Bert N La Du
Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase.
American journal of human genetics 1992;51(4):821-8.
1992: FS Jensen; Cynthia F Bartels; Bert N La Du
Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families.
Pharmacogenetics 1992;2(5):234-40.
1992: Cynthia F Bartels; FS Jensen; Oksana Lockridge; Abraham F L Van Der Spek; H M Rubinstein; T Lubrano; Bert N La Du
DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.
American journal of human genetics 1992;50(5):1086-103.
1992: Cynthia F Bartels; K James; Bert N La Du
DNA mutations associated with the human butyrylcholinesterase J-variant.
American journal of human genetics 1992;50(5):1104-14.
1992: Amiya K Hajra; R C Sorenson; Bert N La Du
Detection of human DNA mutations with nonradioactive, allele-specific oligonucleotide probes.
Pharmacogenetics 1992;2(2):78-88.
1991: Martine Arpagaus; Arnaud Chatonnet; Patrick Masson; M Newton; T A Vaughan; Cynthia F Bartels; C P Nogueira; Bert N La Du; Oksana Lockridge
Use of the polymerase chain reaction for homology probing of butyrylcholinesterase from several vertebrates.
The Journal of biological chemistry 1991;266(11):6966-74.
1991: Bert N La Du; Cynthia F Bartels; C P Nogueira; Martine Arpagaus; Oksana Lockridge
Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing.
Cellular and molecular neurobiology 1991;11(1):79-89.
1991: Bert N La Du
Alcaptonuria and ochronotic arthritis.
Molecular biology & medicine 1991;8(1):31-8.
1991: A Smolen; H W Eckerson; K N Gan; N Hailat; Bert N La Du
Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase.
Drug metabolism and disposition: the biological fate of chemicals 1991;19(1):107-12.
1991: K N Gan; A Smolen; H W Eckerson; Bert N La Du
Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities.
Drug metabolism and disposition: the biological fate of chemicals 1991;19(1):100-6.
1990: Cynthia F Bartels; Abraham F L Van Der Spek; Bert N La Du
Two polymorphisms in the non-coding regions of the BCHE gene.
Nucleic acids research 1990;18(20):6171.
1990: Bert N La Du; Cynthia F Bartels; C P Nogueira; Amiya K Hajra; H Lightstone; Abraham F L Van Der Spek; Oksana Lockridge
Phenotypic and molecular biological analysis of human butyrylcholinesterase variants.
Clinical biochemistry 1990;23(5):423-31.
1990: C P Nogueira; M C McGuire; C Graeser; Cynthia F Bartels; Martine Arpagaus; Abraham F L Van Der Spek; H Lightstone; Oksana Lockridge; Bert N La Du
Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG).
American journal of human genetics 1990;46(5):934-42.
1990: Martine Arpagaus; M Kott; K P Vatsis; Cynthia F Bartels; Bert N La Du; Oksana Lockridge
Structure of the gene for human butyrylcholinesterase. Evidence for a single copy.
Biochemistry 1990;29(1):124-31.
1989: M C McGuire; C P Nogueira; Cynthia F Bartels; H Lightstone; Amiya K Hajra; Abraham F L Van Der Spek; Oksana Lockridge; Bert N La Du
Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(3):953-7.
1988: Bert N La Du
The human serum paraoxonase/arylesterase polymorphism.
American journal of human genetics 1988;43(3):227-9.
1987: C McTiernan; S Adkins; Arnaud Chatonnet; T A Vaughan; Cynthia F Bartels; M Kott; Terrone L Rosenberry; Bert N La Du; Oksana Lockridge
Brain cDNA clone for human cholinesterase.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(19):6682-6.
1987: Oksana Lockridge; S Adkins; Bert N La Du
Location of disulfide bonds within the sequence of human serum cholinesterase.
The Journal of biological chemistry 1987;262(27):12945-52.
1986: Bert N La Du; J I Piko; H W Eckerson; M Vincent-Viry; G Siest
An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism.
Annales de biologie clinique 1986;44(4):369-72.
1986: M Vincent-Viry; Bert N La Du; L Lepage; T Mikstacki
[Distribution of different phenotypes of paraoxonase in a French population].
Annales de biologie clinique 1986;44(3):233-8.
1986: Bert N La Du; S Adkins; R A Bayoumi
Analysis of the serum paraoxonase/arylesterase polymorphism in some Sudanese families.
Progress in clinical and biological research 1986;214():87-98.
1985: E G Butler; H W Eckerson; Bert N La Du
Paraoxon hydrolysis vs. covalent binding in the elimination of paraoxon in the rabbit.
Drug metabolism and disposition: the biological fate of chemicals 1985;13(6):640-5.
1984: Bert N La Du; H W Eckerson
The polymorphic paraoxonase/arylesterase isozymes of human serum.
Federation proceedings 1984;43(8):2338-41.
1984: H W Eckerson; Bert N La Du
A mathematical model for evaluating the reaction of paraoxon with human serum cholinesterase and with polymorphic forms of paraoxonase.
Drug metabolism and disposition: the biological fate of chemicals 1984;12(1):57-62.
1983: H W Eckerson; C M Wyte; Bert N La Du
The human serum paraoxonase/arylesterase polymorphism.
American journal of human genetics 1983;35(6):1126-38.
1983: H W Eckerson; J Romson; C Wyte; Bert N La Du
The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts.
American journal of human genetics 1983;35(2):214-27.
1983: H W Eckerson; A Oseroff; Oksana Lockridge; Bert N La Du
Immunological comparison of the usual and atypical human serum cholinesterase phenotypes.
Biochemical genetics 1983;21(1-2):93-108.
1981: R J Valentino; Oksana Lockridge; H W Eckerson; Bert N La Du
Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies.
Biochemical pharmacology 1981;30(12):1643-9.
1980: Oksana Lockridge; N Mottershaw-Jackson; H W Eckerson; Bert N La Du
Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase.
The Journal of pharmacology and experimental therapeutics 1980;215(1):1-8.